Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.43 |
| ▸ | NOS2 | P35228 | 5/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NAAA | Q02083 | 3/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7636658 | 1.00 | NOS1 (0.43) | NOS1NOS2EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL1168660 | 0.98 | NOS1 (0.44) | NOS1NOS2EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL10707537 | 0.94 | EPHX1 (0.41) | NOS1NOS2EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL7634559 | 0.94 | EPHX1 (0.41) | NOS1NOS2EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL1691768 | 0.92 | NOS1 (0.42) | NOS1NOS2EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL295542 | 0.92 | NOS1 (0.50) | NOS1NOS2CYP1A2NOS3 | |
| SCHEMBL7300362 | 0.91 | SPHK2 (0.39) | NOS1NOS2EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL5214635 | 0.90 | CYP1A2 (0.50) | NOS1NOS2CYP1A2ALDH1A1NOS3 | |
| SCHEMBL7294415 | 0.85 | SPHK2 (0.40) | NOS1NOS2EPHX1ALDH1A1 | |
| SCHEMBL6510677 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2014-05-15 | — | — | US | claimed |
| EP-2727919-A1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) | 2014-05-07 | — | — | EP | claimed |
| EP-2727919-B1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD (CN) | 2019-05-08 | — | — | EP | disclosed |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| US-9296731-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2016-03-29 | — | — | US | disclosed |
| US-8829030-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2014-09-09 | — | — | US | disclosed |
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2014-05-15 | — | — | US | disclosed |
| EP-2727919-A1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) | 2014-05-07 | — | — | EP | disclosed |
| US-8674118-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-04-18 | — | — | US | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| US-5179103-A | Diuretics, hypotensive agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | NR1H4, TST, CYP7A1 | NOS1 1809/4885NOS2 2362/4885EPHX1 681/4885 |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | ZC3HAV1, ZYX, ZFX | NOS1 2971/4885NOS2 2691/4885EPHX1 228/4885 |
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | TST, HRH1, ABCB11 | NOS1 2387/4885NOS2 2713/4885EPHX1 651/4885 |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | NR1H4, TST, CYP7A1 | NOS1 1809/4885NOS2 2362/4885EPHX1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.